{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:34:43Z","timestamp":1777440883898,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/s1470-2045(06)70725-2","type":"journal-article","created":{"date-parts":[[2006,6,3]],"date-time":"2006-06-03T07:18:41Z","timestamp":1149319121000},"page":"499-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Where next for gefitinib in patients with lung cancer?"],"prefix":"10.1016","volume":"7","author":[{"given":"Fiona","family":"Blackhall","sequence":"first","affiliation":[]},{"given":"Malcolm","family":"Ranson","sequence":"additional","affiliation":[]},{"given":"Nick","family":"Thatcher","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(06)70725-2_bib1","series-title":"Etiology and epidemiology of lung cancer","first-page":"367","article-title":"Lung cancer: principles and practice","author":"Schottenfeld","year":"2000"},{"key":"10.1016\/S1470-2045(06)70725-2_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00151829-200504020-00001","article-title":"Improving survival and reducing toxicity with chemotherapy in advanced non-small-cell lung cancer: a realistic goal?","volume":"4","author":"Blackhall","year":"2005","journal-title":"Treat Respir Med"},{"key":"10.1016\/S1470-2045(06)70725-2_bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/S1470-2045(06)70725-2_bib5","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S1470-2045(06)70725-2_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(06)70725-2_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.21496","article-title":"Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers","volume":"118","author":"Shigematsu","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/S1470-2045(06)70725-2_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","article-title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","volume":"4","author":"Sridhar","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/sj.bjc.6601873","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors","volume":"90","author":"Ranson","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(06)70725-2_bib10","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/S1470-2045(06)70725-2_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(06)70725-2_bib13","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib14","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(06)70725-2_bib15","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10637-005-5860-y","article-title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the investigational new drug program of the National Cancer Institute of Canada Clinical Trials Group","volume":"23","author":"Goss","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1016\/S1470-2045(06)70725-2_bib17","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/annonc\/mdg250","article-title":"Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Japanese patients with solid malignant tumors","volume":"14","author":"Nakagawa","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib19","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib21","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-04-0058","article-title":"Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy","volume":"10","author":"Wolf","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(06)70725-2_bib22","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib26","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib27","article-title":"Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small-cell lung cancer (NSCLC)","volume":"23","author":"Gatzemeier","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib28","volume":"23","author":"Kelly","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib30","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(06)70725-2_bib31","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/S1470-2045(06)70725-2_bib32","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1470-2045(06)70725-2_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer\u2014molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(06)70725-2_bib34","unstructured":"Hirsch F, Varella-Garcia M, Bunn P, et al. Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small cell lung cancer treated with gefitinib or placebo (ISEL trial). AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, 2005; Philadelphia, PA, USA: abstr A268."},{"key":"10.1016\/S1470-2045(06)70725-2_bib35","unstructured":"Holloway B, Thatcher N, Chang A, et al. Epidermal growth factor (EGFR), Kras and Braf mutation status and clinical outcome to gefitinib (Iressa) in a phase III placebo-controlled study (ISEL) in advanced non-small cell lung cancer (aNSCLC). Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, 2005; Philadelphia, PA, USA: abstr A269."},{"key":"10.1016\/S1470-2045(06)70725-2_bib36","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","article-title":"Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology","volume":"23","author":"Janne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(06)70725-2_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.10-8-579","article-title":"Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa)","volume":"10","author":"Siegel-Lakhai","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(06)70725-2_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.bjc.6601116","article-title":"ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases","volume":"89","author":"Cappuzzo","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(06)70725-2_bib53","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.cad.0000203381.99490.ab","article-title":"Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (Iressa) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer","volume":"17","author":"Cufer","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/S1470-2045(06)70725-2_bib56","article-title":"Randomised phase II\/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599","volume":"23","author":"Sandler","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/S1470-2045(06)70725-2_bib57","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0169-5002(05)80237-5","article-title":"A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC: Results of a double-blind phase II study","volume":"49","author":"Natale","year":"2005","journal-title":"Lung Cancer"}],"updated-by":[{"DOI":"10.1016\/s1470-2045(07)70218-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000}}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204506707252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204506707252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:54:07Z","timestamp":1761458047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204506707252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S1470204506707252"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(06)70725-2","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where next for gefitinib in patients with lung cancer?","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(06)70725-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}